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Introduction
Central nervous system (CNS) dissemination has been reported in 2-10% of diffuse large B-cell lymphoma (DLBCL) patients. 1, 2 Whereas relatively uncommon it is fatal in more than 90% of patients. 3, 4 Most CNS metastases occur in the setting of DLBCL relapse and their treatment is mostly palliative 5 . The factors most consistently associated with risk of CNS recurrence are elevated serum lactate dehydrogenase and involvement of more than one extranodal site. [6] [7] [8] [9] CNS-directed prophylactic intrathecal therapy is often used to reduce the risk of CNS recurrence in these patients but its benefit has been questioned in recent years. 1, 10, 11 The addition of rituximab to standard cyclophosphamide, doxorubicin, vincristin and prednisone (CHOP), has improved the outcome of DLBCL patients, [12] [13] [14] [15] [16] but the protective effect of rituximab on CNS recurrence is controversial. 2, [17] [18] [19] [20] [21] Thus, the optimal treatment for CNS dissemination in DLBCL has not been established thus far and new therapies are needed in order to prevent or treat this fatal condition. However, the lack of appropriate animal models that reproduce CNS involvement in DLBCL hinders the development of new drugs.
Brain metastasis is a multistep process of tumor cell attachment to microvessel endothelial cells, extravasation into the brain, interaction with the local microenvironment and proliferation. This process involves precise regulation of cell-cell adhesion and cell-extracellular matrix (ECM) adhesion. 22, 23 The cell-ECM adhesion is maintained by the focal adhesion complexes, composed of transmembrane receptors known as integrins, structural proteins (i.e., vinculin, talin, paxilin…) and signaling proteins (i.e., FAK, p130Cas, HEF1, Pyk2...). 24 A critical step in the CNS metastasis process is tumor cell adhesion to the vascular basement membrane of the brain, which is mediated by integrin signaling. 25, 26 Thus, agents that efficiently block tumor cell adhesion mediated by focal adhesion signaling in DLBCL may prevent CNS progression.
Recently, we found that E7123, a novel non-COX-2 celecoxib derivative capable of inhibiting focal adhesion signaling, had in vitro antitumor effect against DLBCL cell lines and reduced tumor volume in a NOD/SCID subcutaneous model of DLBCL. 27 Our group has also shown that subcutaneous conditioning of cells prior to intravenous injection of DLBCL cell lines increased tumor take rate and cell dissemination capacity as compared to direct intravenous injection in NOD/SCID mice. 28 In this paper, we aimed to evaluate the therapeutic effect of E7123 in a novel xenograft mouse model of DLBCL with CNS involvement. The animal model was generated by performing a subcutaneous passage of HT cells --which had previously shown CNS tropism after direct intravenous injection--before their intravenous injection in NOD/SCID mice.
Methods
Cell line and compounds. HT human DLBCL cell line (DMSZ Cell Line Bank) was cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1% glutamine, 100 units/ml penicillin/streptomycin (Life 
Results
Subcutaneous passage of the HT cell line enhanced engraftment
In previous studies, we observed that direct intravenous injection of DLBCL cells in NOD/SCID mice showed inefficient take rate and took a long time to generate lymphoma. However, when we performed a subcutaneous passage of the same DLBCL cell lines before their intravenous injection in mice, their aggressiveness was dramatically increased, producing a disseminated lymphoma in all mice in a short period of time. 28 In a preliminary experiment, we observed that direct intravenous injection of HT cells produced lymphoma in 2 of 10 mice at 66 and 74 days after injection and that both mice showed CNS infiltration. In order to increase the take rate and the aggressiveness of these cells, we performed a subcutaneous passage of HT cells before their intravenous injection and compared their take rate and the animal survival with control mice directly injected with HT cells, without previous subcutaneous passage (see Material and Methods section). Cells obtained after disaggregation of HT subcutaneous tumors were named HT-SC cells. In the intravenously injected HT-SC group, one mouse had to be excluded from the experiment as a tumor developed in the injection point. The remaining mice in this group (n=7) were euthanized between days 40 and 51 post-injection, when they reached a 15% weight loss. In contrast, only 2 out of 10 HT control mice were euthanized, at days 78 and 89 after injection as a consequence of weight loss. The remaining mice in the HT control group were sacrificed at day 100 without any sign of disease, and their histopathological analysis revealed no tumor development. Survival times for both groups were statistically different (p<0.01) as shown by Kaplan-Meier survival curves in Figure 1A .
Interestingly, mice from the experimental HT-SC group showed a visible cranial inflammation at about day 30 after injection.
Intravenous injection of HT-SC cells generated DLBCL in the CNS
Most mice showed motor difficulties -generally circular motion-before being sacrificed. At necropsy, we observed that mice from the experimental group showed an evident cranial inflammation in comparison with mice from the HT control group ( Figure 1B) . When analyzed microscopically, we observed that 100%
of HT-SC mice showed brain infiltration -especially in leptomeninges- (Figure 2A -H), whereas only 1 out of 2 infiltrated HT control mice showed this involvement (Table 1) . Infiltrated brains of the HT-SC mice were positive for CD20 (B-cell antigen) ( Figure 2I ) and CD10 (germinal centre marker) ( Figure 2J) immunostaining, confirming that HT-SC cells maintained the germinal centre DLBCL phenotype found in the original HT cells. Immunostaining with the proliferation marker Ki67 ( Figure 2K ) showed a proliferation index of 70-80% in all lymph nodes, a common proliferation rate in DLBCL pathology.
HT-SC cells showed higher p130Cas and β
1-integrin expression than HT cells
Based on previous evidences showing that in vivo passages were associated with changes in adhesion properties 28, 31-33 and that the expression of some adhesion molecules could be associated with CNStropism, 23, 25 we studied the expression of 
E7123 increased survival time in the DLBCL animal model with CNS involvement
Ten days after intravenous injection of HT-SC cells, mice were randomly allocated into two groups and treated orally with 75 mg/kg E7123 or vehicle. Mice were treated every day until they were sacrificed for weight loss or signs of sickness. We used PEG-400:FBS 3:1 as a vehicle because it showed no toxicity in healthy mice and permitted the total solubilization of E7123 without changing its antitumor activity in vitro 27 . All mice receiving vehicle were sacrificed between days 39 and 48 post-injection. However, mice receiving E7123 were sacrificed between 43 and 85 days after injection. The difference in survival time between both groups was statistically significant (p=0.01) as assessed by Log rank test (Table 2 ).
Microscopic infiltration of brain, lymph nodes or bone marrow of all mice is also described in Table 2 .
E7123 increased survival time in a validation experiment using a bioluminescent mouse model of DLBCL with CNS infiltration.
In order to validate the antitumor effect of E7123 in the new xenograft model of DLBCL disseminated to the CNS, we performed the same procedure using bioluminescent subcutaneously-conditioned HT cells (HT-Luc-SC).
As explained in Materials and Methods section, HT-Luc-SC cells were intravenously injected in 20 NOD/SCID mice, which were randomly divided in two groups receiving vehicle or 75 mg/kg E7123. The first CNS bioluminescent signal was observed in 3 vehicle-treated and 2 E7123-treated mice on day 17 post-injection. CNS bioluminescence was observed in all mice between days 17 and 57 after cell injection. Figure 4A shows the time course BLI signal in CNS of vehicle and E7123-treated representative mice. We could observe that BLI signal in the CNS of the vehicle-treated mouse increased faster than in the E7123-treated mouse. BLI intensity quantification curves for both groups are represented in Figure   4B . Thus, DLBCL cell growth in CNS was delayed in E7123-treated mice. However, E7123 did not block lymphoma cell invasion of the CNS since there were no significant differences in the time of initial detection of CNS BLI signal between groups.
E7123 also increased mice survival time in this model since vehicle-treated mice were killed between 36
and 58 days post-injection, whereas E7123-treated mice were euthanized between 48 -91 days after injection ( Figure 4C ). Two mice from each group were excluded from the experiment because they did not develop lymphoma. The histopathological features and clinical evolution of HT-Luc-SC injected mice are detailed in Table 3 .
Thus, we confirmed that E7123 increased mouse survival time in a bioluminescent model of DLBCL with CNS infiltration. In addition, as observed in the luminescent images, E7123 slowed down the growth of lymphoma cells within CNS.
Discussion
In this study, we showed that the oral administration of a novel focal adhesion inhibitor, E7123, increased survival of mice with DLBCL involving the CNS. The subcutaneous passage of HT cells before their intravenous injection in NOD/SCID mice permitted to generate a xenograft model of DLBCL with CNS involvement that can be used for evaluation of drugs for this malignancy. We observed that during the subcutaneous passage, HT cells acquired an increased expression level of β 1-integrin and p130Cas
proteins. This increased expression was associated with enhanced aggressiveness and CNS tropism of lymphoma cells.
The outcome of DLBCL patients with CNS occurrence is extremely poor and they do not appear to benefit from current prophylactic protocols. 2, 9-11 Thus, there is a need to develop new treatments for this fatal condition. However, the development of new therapies against this malignancy is hindered by the lack of appropriate animal models to evaluate them. Some authors reported xenograft models of primary CNS lymphoma (PCNSL) performed after injection of the aggressive Burkitt's lymphoma cells directly into the brain, [34] [35] [36] [37] whereas others generated syngeneic models of CNS lymphoma after intraocular or intracerebral injection of murine lymphoma cells in immunocompetent hosts. 38, 39 An important advantage of the latter models in respect to xenograft models of CNS lymphoma using immunodeficient mice is that syngeneic models allow the study of tumor-induced immunity. 40, 41 However, they are technically difficult to perform and they do not use human DLBCL cells. Here, we generated a rapid xenograft model of In a previous study, the non-COX2 inhibitor celecoxib derivative E7123 showed an in vitro antitumor effect in different DLBCL cell lines by deregulation of focal adhesion proteins, which were expressed in the majority of human DLBCL patient samples. The oral administration of E7123 was well tolerated and reduced tumor growth in a subcutaneous xenograft of DLBCL. 27 In this paper, we showed that the focal adhesion inhibitor E7123 increases mice survival time in two independent experiments using a new parent compound, celecoxib, crossed the blood-brain barrier 46 and prolonged mice survival time in a xenograft model of PCNSL. 36 The clinical use of celecoxib, however, is associated with risk of cardiovascular events associated with COX-2 inhibition. 47 E7123, in contrast, does not inhibit COX-2.
Thus, E7123 is likely to be effective for the treatment of CNS relapse in DLBCL without showing cardiovascular toxicity. Considering the unproven efficacy of current drugs in CNS relapse treatment and the physical discomfort associated with intrathecal administration, orally available E7123 could be an alternative treatment in combination with current therapy to treat CNS involvement in DLBCL in the future.
In conclusion, E7123 is a new, well tolerated and orally bioavailable therapeutic agent that increases survival time in a novel xenograft model of DLBCL with CNS involvement. We consider E7123 merits further investigation as findings to date suggest it may improve current management and quality of life of DLBCL patients with this fatal condition.
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